GENinCode (LON:GENI) Shares Down 20% – Time to Sell?

Shares of GENinCode Plc (LON:GENI) dropped 20% during trading on Tuesday. The company traded as low as GBX 0.64 and last traded at GBX 0.70. Approximately 22,954,143 shares were traded during mid-day trading, an increase of 346% from the average session volume of 5,146,545 shares. The stock had previously closed at GBX 0.88.

GENinCode Stock Down 3.3%

The company has a quick ratio of 15.88, a current ratio of 2.22 and a debt-to-equity ratio of 4.75. The firm has a market capitalization of £5.10 million, a PE ratio of -0.33 and a beta of 0.59. The company’s fifty day simple moving average is GBX 0.88 and its 200 day simple moving average is GBX 0.98.

GENinCode (LON:GENI) last released its earnings results on Tuesday, September 29th. The company reported GBX (0.38) earnings per share for the quarter. GENinCode had a negative return on equity of 481.34% and a negative net margin of 202.42%. Analysts anticipate that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.